Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck(German Center for Lung Research), Federico Cappuzzo(Ospedale di Livorno), Denis Moro‐Sibilot(Centre Hospitalier Universitaire de Grenoble), Naoyuki Nogami(Hospital Universitario Insular de Gran Canaria), Francesco Orlandi(Instituto Nacional del Tórax), Anthony Lee, Robert M. Jotte(Sarah Cannon), Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), Tony Mok(Chinese University of Hong Kong), Daniil Stroyakovskiy(Shikoku Cancer Center), Christian A. Thomas(Centre National de la Recherche Scientifique), Makoto Nishio(Japanese Foundation For Cancer Research), Yu Deng(Capital Medical University), Fabrice Barlési(Hôpital Nord), Wei Lin(Florida Hospital Cancer Institute), Marcin Kowanetz, Geetha Shankar
Cited by 937
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k